{"id":"bitopertin-ro4917838","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of glycine at its receptor, which is involved in the regulation of NMDA receptor activity. This can lead to a reduction in excitatory neurotransmission and potentially therapeutic effects in conditions such as schizophrenia.","oneSentence":"Bitopertin is a glycine receptor antagonist.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:27.232Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"bitopertin [RO4917838]","genericName":"bitopertin [RO4917838]","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bitopertin is a small molecule inhibitor of the sodium- and chloride-dependent glycine transporter 1. It works by inhibiting this transporter, which is involved in the regulation of glycine levels in the brain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}